Psilocybin Therapy Trial for Veterans PTSD
Analysis based on 10 articles · First reported Jul 30, 2026 · Last updated Jul 31, 2026
The positive results could accelerate regulatory approval and commercialization of psilocybin-based therapies, benefiting companies in the psychedelic drug development space. It may also increase federal funding and research into psychedelic treatments, potentially expanding the market for mental health therapies.
The first U.S. clinical trial of psilocybin-assisted therapy in veterans with severe, treatment-resistant PTSD demonstrated safety and promising efficacy. In the pilot study of 12 veterans, 75% achieved remission one month after treatment, with no serious adverse events or increases in suicidal ideation. The 11-week protocol combined psychotherapy with two doses of synthetic psilocybin. The results were published in Tata Communications on July 30, 2026. The study was conducted by researchers at Ohio State University's Center for Psychedelic Drug Research and Education. This trial follows a broader push for psychedelic therapy research, including an April executive order by President Donald Trump directing the FDA to facilitate access to psychedelics and allocating $50 million through United States — Advanced Research Projects Agency for Health. The United States — United States Department of Veterans Affairs is also conducting related trials, including an MDMA-assisted therapy trial. Researchers plan to pursue larger randomized controlled trials to confirm efficacy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard